New injection aims to stop cancer wasting

NCT ID NCT07237464

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called GB18 in 36 healthy adults to see if it is safe and how the body handles it. The drug is designed to treat cancer cachexia, a condition where cancer patients lose weight and muscle. Participants receive a single injection of GB18 or a placebo, and researchers monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GB18

What this could lead to

If it works, this could point toward a treatment for cancer cachexia, a condition causing severe weight loss and muscle wasting in cancer patients.

What could go wrong

This is a very early Phase 1 trial in healthy people, not cancer patients. It only tests safety and dosing, so it may not work for cachexia or may have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact